CLINICAL TRIAL SUMMARY

MDACC Study No:2009-0902 (clinicaltrials.gov NCT No: NCT01063907)
Title:An Open-Label, Dose Escalation, Multicenter Phase I/2 Study of KW-2478 in Combination with Bortezomib in Subjects with Relapsed and/or Refractory Multiple Myeloma
Principal Investigator:Robert Orlowski
Treatment Agent:Bortezomib; KW-2478
Study Status:Closed
Study Description:The goal of Phase I of this clinical research study is to find the highest
tolerable doses of KW-2478 and bortezomib when given in combination to
patients with MM.

The goal of Phase II of this clinical research study is to learn if KW-2478 in
combination with bortezomib can help to control MM. The safety of this drug
combination will be studied in both phases.

Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase I/Phase II
Treatment Agents:Bortezomib
KW-2478
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:None
Supported By:Kyowa Hakko Kirin Pharma, Inc.
Return Visit:5 visits per cycle.
Home Care:None


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Robert Orlowski
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults